Dupilumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL4 receptor alpha |
| Identifiers | |
| CAS Number | 1190264-60-8 |
| ATC code | None |
| ChemSpider | none |
| Chemical data | |
| Formula | C6512H10066N1730O2052S46 |
| Molar mass | 146.9 kg/mol |
Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases.[1] It binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα).[2] Through blockade of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathway, which have been implicated in the pathophysiology of allergic disease, particularly asthma and atopic dermatitis.[3]
This drug was developed by Regeneron Pharmaceuticals.
In 2013 mid-stage data was presented at the American Thoracic Society meeting and published in the NEJM demonstrating an 87% (placebo: 67%) reduction in asthma exacerbations in patients with moderate-to-severe allergic asthma.[2] In an atopic dermatitis study, 85% of patients improved their symptoms by at least 50% within twelve weeks (measured by eczema area and severity index), versus 35% in the placebo group.[4]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Dupilumab, American Medical Association.
- 1 2 Dupilumab in Persistent Asthma with Elevated Eosinophil Levels - Sally Wenzel, M.D., Linda Ford, M.D., David Pearlman, M.D., Sheldon Spector, M.D., Lawrence Sher, M.D., Franck Skobieranda, M.D., Lin Wang, Ph.D., Stephane Kirkesseli, M.D., Ross Rocklin, M.D., Brian Bock, D.O., Jennifer Hamilton, Ph.D., Jeffrey E. Ming, M.D., Ph.D., Allen Radin, M.D., Neil Stahl, Ph.D., George D. Yancopoulos, M.D., Ph.D., Neil Graham, M.D., and Gianluca Pirozzi, M.D., Ph.D., NEJM.
- ↑ Regeneron press release March 2, 2013
- ↑ H. Spreitzer (16 March 2015). "Neue Wirkstoffe – Dupilumab". Österreichische Apothekerzeitung (in German) (6/2015): 16.